{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T20:48:10Z","timestamp":1761598090780},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"5","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDDT"],"published-print":{"date-parts":[[2020,12,23]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p> Rheumatoid Arthritis (RA) is a complex disease involving an unknown number\nof genes, and affecting a large number of organs, tissues, and sites across the body. It is affecting approximately\n1% of the population worldwide. The safety and therapeutic efficacy of \u03b2-D-mannuronic acid\n(M2000) as a novel NSAID with immunosuppressive property has been demonstrated under in vitro, in\nvivo examinations and clinical trials phase 1\/11 in Ankylosing Spondylitis (AS) patients in addition to\nphase I\/11 and 111 in Rheumatoid Arthritis (RA) patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>In this study, our goal is to evaluate the therapeutic efficacy of oral administration of M2000\non gene expression of the matrix metalloproteinase (MMP2, MMP9) and tissue inhibitor of metalloproteinase\n(TIMP1, TIMP2) as inflammatory molecules in the progression of rheumatoid arthritis.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>The study has included 15 RA patients who had an insufficient response to the conventional\ndrug. Therefore, mannuronic acid was used as an additive to the conventional regime. The research was a\nsingle-blinded study. The dose of M2000 was 500mg orally twice per day for 12 weeks. There were 15\nhealthy participants considered as control. Blood samples have been collected from both groups once\nfrom the healthy control and twice from RA patients before and after treatment with M2000. The Peripheral\nBlood Mononuclear Cells (PBMCs) were isolated for assessment of the gene expression level of\nMMP2, MMP9, TIMP1, and TIMP2 using the real-time PCR method.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p> The gene expression level of MMP2 and MMP9 reported a significant reduction in RA patients\nafter treatment with M2000 compared to before treatment. On the other hand, the gene expression level\nof TIMP2 demonstrated a significant increase in RA patients after treatment with mannuronic acid compared\nto before treatment, but there was no significant difference between the group of RA patients before\ntreatment and the control group. Vice versa to other molecules, there was no significant difference in\nthe level of TIMP1 in compression with RA patients before and after treatment.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>our findings proved that the \u03b2 -D- mannuronic acid) as a novel NSAID with immunosuppressive\nproperty has a significant effect on the gene expression level of MMP2, MMP9 and TIMP2\nmolecules in RA patients.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1570163816666190620113320","type":"journal-article","created":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T06:52:36Z","timestamp":1561963956000},"page":"704-710","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Oral Administration Effect of Drug Mannuronic Acid (M2000) on Gene Expression of Matrix and Tissue Inhibitor of Metalloproteinases in Rheumatoid Arthritis Patients"],"prefix":"10.2174","volume":"17","author":[{"given":"Nada A.G.","family":"Gaafar","sequence":"first","affiliation":[{"name":"Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona","family":"Aslani","sequence":"additional","affiliation":[{"name":"Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Aghazadeh","sequence":"additional","affiliation":[{"name":"Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Razavi","sequence":"additional","affiliation":[{"name":"Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abbas","family":"Mirshafiey","sequence":"additional","affiliation":[{"name":"Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","container-title":["Current Drug Discovery Technologies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/172862","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/172862\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/172862","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,28]],"date-time":"2020-12-28T14:44:13Z","timestamp":1609166653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/172862\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,23]]},"references-count":0,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,12,23]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570163816666190620113320","relation":{},"ISSN":["1570-1638"],"issn-type":[{"value":"1570-1638","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12,23]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-03-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-07","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}